Literature DB >> 8241667

Variation in serum C-reactive protein across the clinical spectrum of meningococcal disease.

O Marzouk1, K Bestwick, A P Thomson, J A Sills, C A Hart.   

Abstract

In a multicentre prospective study, 124 cases of meningococcal disease were classified into the clinical categories, meningitis alone (n = 15), meningitis and septicaemia (n = 79) and septicaemia alone (n = 30). A further 60 children referred with other illnesses served as controls. Serial measurements of serum C-reactive protein (admission, day 1, day 2, days 5-7) were compared. Children with septicaemia had significantly lower C-reactive protein levels on admission than those with meningitis alone or meningitis and septicaemia which were unexplained by differences in the duration of the presenting illness or severity of the disease. Within each clinical category of meningococcal disease, significant changes in C-reactive protein concentration occurred during the course of the disease. Four control children had other types of septic meningitis: admission C-reactive protein concentrations did not differ from those with meningitis or meningitis and septicaemia, but were significantly higher than those with septicaemia alone. The other 56 patients had a significantly lower admission C-reactive protein concentration compared with all cases of meningococcal disease. For the diagnosis of meningococcal disease, admission C-reactive protein levels of > or = 40 mg/l had a sensitivity of 79%, specificity of 80% and positive predictive value of 87%. For the prognostic prediction of death in meningococcal disease (or meningococcal disease with shock) CRP < 100 mg/l on admission had a sensitivity of 69% (69%), specificity of 50% (56%) and positive predictive value of 18% (53%). In children with suspected meningococcal disease, serum C-reactive protein, measured on admission, has diagnostic value but not prognostic value.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8241667     DOI: 10.1111/j.1651-2227.1993.tb12547.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  8 in total

1.  The management of fever and petechiae: making sense of rash decisions.

Authors:  P A Brogan; A Raffles
Journal:  Arch Dis Child       Date:  2000-12       Impact factor: 3.791

2.  Elevated procalcitonin as a diagnostic marker in meningococcal disease.

Authors:  G D Mills; H M Lala; M R Oehley; A B Craig; K Barratt; D Hood; C N Thornley; A Nesdale; N E Manikkam; P Reeve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-08       Impact factor: 3.267

3.  Procalcitonin as a diagnostic marker of meningococcal disease in children presenting with fever and a rash.

Authors:  E D Carrol; P Newland; F A I Riordan; A P J Thomson; N Curtis; C A Hart
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

4.  Diagnostic assessment of haemorrhagic rash and fever.

Authors:  H E Nielsen; E A Andersen; J Andersen; B Böttiger; K M Christiansen; P Daugbjerg; S O Larsen; I Lind; M Nir; K Olofsson
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

5.  Severity scores in meningococcal septicemia and severe infectious purpura with shock.

Authors:  F Leclerc; F Delepoulle; J F Diependaele; A Martinot; V Hue; V Flurin; C Fourier; M Chenaud
Journal:  Intensive Care Med       Date:  1995-03       Impact factor: 17.440

6.  Bacterial meningitis after MMR immunisation.

Authors:  F A Riordan; J A Sills; A P Thomson; C A Hart
Journal:  Postgrad Med J       Date:  1995-12       Impact factor: 2.401

7.  The child with a non-blanching rash: how likely is meningococcal disease?

Authors:  L C Wells; J C Smith; V C Weston; J Collier; N Rutter
Journal:  Arch Dis Child       Date:  2001-09       Impact factor: 3.791

8.  Diagnostic markers of infection: comparison of procalcitonin with C reactive protein and leucocyte count.

Authors:  M Hatherill; S M Tibby; K Sykes; C Turner; I A Murdoch
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.